There are currently 1877 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737
Recruiting
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/25/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Cutaneous Lupus Erythematosus
Register for Updates
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
NCT06111586
Recruiting
This is a randomized, parallel group, double-blind Phase 2 study with a 52-week blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. Study details include: Screening period: at least 3 weeks and up to 5 weeks Double-blind treatment period (104 weeks): * Main treatment period: 52 weeks * Blinded extension: 52 weeks Safety follow-up: up to 26 weeks The treatment duration wil... Read More
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
06/25/2025
Locations: The Children's Hospital of Philadelphia Site Number : 8400005, Philadelphia, Pennsylvania
Conditions: Type 1 Diabetes Mellitus
Register for Updates
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213
Recruiting
Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagno... Read More
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
06/25/2025
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Focal Onset Seizure
Register for Updates
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
NCT05945849
Recruiting
The purpose of this study is to provide a new type of treatment for AML. This treatment combines a new type of stem cell transplant along with treatment using chimeric antigen receptor (CAR) T cells that have been engineered to recognize and attack your AML cells. The first treatment is a modified stem cell transplant, using blood-forming stem cells donated from a healthy donor. From the same donor, we will also make CAR T-cells, which are leukemia fighting cells, which will be given to the pat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927
Recruiting
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619
Recruiting
The primary objective of the trial is to evaluate the efficacy of fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electronic module (Fp/ABS eMDPI). Secondary objectives are: * To evaluate the efficacy of Fp/ABS eMDPI administered four times daily * To evaluate the safety and tolerability of Fp/ABS eMDPI administered four times daily over four weeks * To investigate the pharmacokinetics of Fp/ABS eMDPI, ABS eMDPI and Fp eMDPI after administration of a single dose The... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/25/2025
Locations: Teva Investigational Site 12072, Philadelphia, Pennsylvania
Conditions: Asthma
Register for Updates
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123
Recruiting
This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Cardiovascular Disease
Register for Updates
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
MALE
Ages:
Between 18 years and 130 years
Trial Updated:
06/25/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Metastatic Castration-Sensitive Prostate Cancer
Register for Updates
Advancing Transplantation Outcomes in Children
NCT06055608
Recruiting
This is a pediatric kidney transplant study comparing the safety and efficacy of an immunosuppressive regimen of belatacept and sirolimus to tacrolimus and Mycophenolate Mofetil (MMF). Two hundred participants will be randomized (1:1) to one of two groups within 24 hours following the transplant procedure. The duration of the study from time of transplant to the primary endpoint is 12-24 months.
Gender:
ALL
Ages:
Between 13 years and 20 years
Trial Updated:
06/25/2025
Locations: Children's Hospital of Philadelphia (Site #: 71091), Philadelphia, Pennsylvania
Conditions: Kidney Transplant
Register for Updates
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
NCT06248619
Recruiting
The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/25/2025
Locations: Scheie Eye Institute, Philadelphia, Pennsylvania
Conditions: Thyroid Eye Disease
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD
NCT06883305
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
06/25/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
NCT06671912
Recruiting
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, pre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania +1 locations
Conditions: Anatomic Stage 0 Breast Cancer AJCC V8, Anatomic Stage 1 Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Register for Updates